INTRODUCTION
Allergic disorders are widespread, particularly in developed countries (1) . Allergic responses are associated with increases in the number of T helper 2 (T H 2) cells and immunoglobulin E (IgE) antibody production. Presentation of allergen to antigen-presenting cells (APCs) causes T H 2 cells to produce T H 2-type cytokines. In particular, the cytokine interleukin-4 (IL-4) is essential for the isotype switching of B cells to produce allergen-specific IgE antibodies (2) , which then bind specifically to the multimeric highaffinity IgE receptor FceRI (3) on mast cells and basophils.
B cells are generally known for their capacity to regulate effector T cell responses and to produce antibodies (4); however, studies in murine disease models revealed some distinct B cell subsets that exhibit immunosuppressive functions (5) (6) (7) (8) and thus are named regulatory B (B reg ) cells (9) . Other subsets of B reg cells have also been identified to suppress various immune responses in an IL-10-dependent manner (10) , whereas helminth infection-induced IL-10-producing B cells inhibit allergic reactions in animal models, specifically ovalbumin-mediated anaphylaxis (11) and allergic asthma (12) . IL-10 also suppresses mast cell activation in vitro and in vivo and may thus counteract their excessive activation and the development of chronic inflammation (13, 14) . Despite these reports, and given the role of mast cells in these and other allergic diseases (15, 16) , surprisingly little is known about the mechanism of interaction between B reg cells and mast cells or about the consequences of these interactions for IgE-mediated allergic responses.
Mast cells are the key effector cells in IgE-mediated allergic reactions. These cells are widely distributed in vascularized tissues, especially near surfaces exposed to the environment, such as the skin, airways, and the gastrointestinal tract (15) . Mast cells are commonly activated by the multivalent binding of antigen to FceRI-bound IgE, with the subsequent release of various allergic mediators, including histamine, eicosanoids, and inflammatory cytokines. Release of these mediators leads to immediate, and sometimes delayed, symptoms of allergic diseases, such as allergic rhinitis, anaphylaxis, and atopic dermatitis (17, 18) . We found that CD5 + B cells inhibited IgE-mediated mast cell activation and anaphylaxis in mice in an IL-10-dependent manner. Furthermore, we found that IL-10-producing CD5 + B cells inhibited the activation of the tyrosine kinase Syk (spleen tyrosine kinase) in mast cells. Together, our findings suggest that IL-10-producing CD5 + B cells inhibit IgE-mediated allergic responses in physiological settings.
RESULTS

CD5
+ B cells suppress IgE-mediated anaphylaxis in vivo and mast cell activation in vitro IgE-dependent mast cell activation is regarded as one of the cardinal mechanisms in the development of anaphylaxis. Here, we administrated IgE antibody and antigen intravenously to mice to induce passive systemic anaphylaxis (PSA), and these responses are essentially associated with extensive mast cell activation in vivo. We found that the numbers of IL-10-producing CD5 + B cells were increased in the spleen, peritoneal cavity, lymph node, and blood of IgE-and antigen-induced PSA mice ( fig. S1A ), which suggests that these cells are associated with the progression of symptoms. We next examined CD19-decifient mice in which IL-10-producing B cells are substantially depleted (fig. S1B) (7) . We found that IgE-mediated anaphylaxis responses (Fig. 1A) and increases in the concentration of histamine in the blood (Fig. 1B) were substantially enhanced in the CD19-deficient mice compared to wild-type mice.
To assess the effects of CD5 + B cells in IgE-mediated allergic responses in vivo, we first induced PSA in CD19-deficient mice. Three days after they received purified CD5 + or CD5 − B cells from wild-type mice by adoptive transfer ( fig. S1C ), IgE-sensitized CD19-deficient mice were intravenously challenged with antigen. The presence of CD5 + B cells, but not CD5 − B cells, markedly alleviated the decline in temperature in response to antigen (Fig. 1C) . Serum histamine concentrations were increased in antigen-challenged mice compared to those in unchallenged mice, but this increase was substantially reduced after the adoptive transfer of CD5 + cells (Fig. 1D ). Next, we found that culturing BMMCs with CD5 + B cells, but not CD5 − B cells, substantially inhibited their degranulation in response to antigen in a time-and cell concentration-dependent manner (Fig. 1 , E and F), as well as inhibited their release of other allergic mediators, such as histamine, TNF-a, and IL-4 ( Fig. 1, G to I ). This inhibitory action of CD5 + B cells was not dependent on mouse strain or tissue source because CD5 + B cells isolated from the peritoneal cavity of C57BL/6 mice and from the spleen of BALB/c mice also inhibited the antigen-stimulated degranulation of BMMCs (fig. S1, D and E).
IL-10 from CD5 + B cells is critical for mast cell inhibition
The immunoregulatory role of B reg cells, also called B10 cells, is generally dependent on IL-10 (10). We found that the passive cutaneous anaphylaxis (PCA) reaction was increased in IL-10 −/− mice compared to that in wild-type mice ( fig. S2, A and B, top) . The numbers of degranulated mast cells in the ear tissues of IL-10 −/− mice were increased, albeit not statistically significantly, compared to those in the ear tissues of wildtype mice ( fig. S2B, bottom) . These results led us to investigate whether with the indicated combinations of IgE and antigen. The amounts of histamine (G), tumor necrosis factor-a (TNF-a) (H), and IL-4 (I) released into the culture medium were determined by enzyme-linked immunosorbent assay ELISA). Data are means ± SEM of three independent experiments. *P < 0.05; **P < 0.01; n.s., not significant.
IL-10 generated by CD5 + B cells inhibited mast cell activation and IgEmediated anaphylaxis. First, we found that monoclonal antibodies against IL-10 or the IL-10 receptor (IL-10R) blocked the suppressive effect of CD5 + B cells on the antigen-induced degranulation of BMMCs ( Fig. 2A) . Second, CD5 + B cells from IL-10 −/− mice failed to inhibit the IgE-and antigen-stimulated degranulation of BMMCs in vitro (Fig. 2B ).
CD5
+ B cells from either wild-type or IL-10 −/− mice showed no statistically significant differences in the amounts of their cell surface markers, including IgD, IgM, CD19, CD21, CD1d, CD11b, CD40, and B220 ( fig.  S2C ). Third, CD5 + B cells also inhibited the antigen-stimulated degranulation of IL-10 −/− BMMCs ( fig. S2D) . Notably, flow cytometric analysis revealed that IL-10-producing B cells were found mostly within a Direct cell-cell contact is essential to inhibit mast cell activation and enhance IL-10 production by CD5 + B cells
Although degranulation was inhibited when mast cells were cultured with CD5 + B cells, this was not the case when the cell types were physically separated in transwell culture flasks (Fig. 3A) . Note that conjugation of CD5 + B cells and mast cells with or without IgE (~20% of cells conjugated) was observed in cocultures, and the extent of conjugation was increased (to~2 5%) by the addition of antigen (Fig. 3 , B and C). We also observed conjugation between CD5 − B cells and mast cells ( fig. S3F ), which was similar to that between CD5 + B cells and mast cells. Furthermore, immunohistochemical analysis of mouse spleens after PSA was induced revealed that some CD5 + CD19
+ B cells were in close proximity to mast cells, which raises the possibility of crosstalk between these two cell types in vivo (Fig.  3D) . Similarly, the increase in IL-10 production by CD5 + B cells was observed only in cocultures and not when both cell types were separated in transwell flasks ( of IL-10 (10). Because the abundance of CD40 ligand (CD40L) on the surface of mast cells is increased by stimulation with antigen (19), we determined whether the enhanced IL-10 production by B cells was dependent on the CD40-CD40L interaction. The abundances of CD40 on B cells and IL-10 in B cells, as well as the amount of IL-10 secreted from B cells, were substantially increased by recombinant CD40L (Fig. 4 , A to D). Whereas CD40 abundance and IL-10 production in whole B cells were increased when they were cocultured with BMMCs ( fig. S4 , A and B), IL-10 production by B cells was largely blocked in the presence of an anti-CD40L monoclonal antibody ( fig. S4 , B and C). In addition, in cocultures of CD5 + B cells and BMMCs, the increased abundances of cell surface CD40 (Fig. 4E ) and IL-10 (Fig. 4 , F and G) in CD5 + B cells were markedly inhibited by the anti-CD40L antibody, and the suppressive action of CD5 + B cells on BMMC degranulation was also blocked by this antibody (Fig. 4H) .
The interaction between CD5
+ B cells and mast cells through CD40-CD40L is critical for the suppression of IgE-mediated mast cell activation and anaphylaxis (Fig. 5, C and D) , which was consistent with the data obtained from experiments with recombinant CD40L and the anti-CD40L antibody (Fig. 4) , as well as with the requirement of CD40-CD40L interaction for IL-10 production by CD5 + B cells. Moreover, this interaction appeared to be necessary irrespective of whether the BMMCs were stimulated with antigen (Fig. 5, C and D) . Loss of either CD40 or CD40L did not alter the patterns of cell surface markers of CD5 + B cells or BMMCs, respectively ( fig. S4D) .
With respect to mast cell function, the IgE-and antigen-induced degranulation of BMMCs was no longer suppressed when CD40 −/− CD5 + B cells or CD40L −/− BMMCs were substituted for the corresponding wildtype cells (Fig. 5E) anti-CD40L antibody, and isotype control antibody were stimulated with IgE and antigen, as indicated. Twenty-four hours later, the extent of b-hexosaminidase release into the culture medium was determined. Plots in (B) and (F) are representative of three independent experiments. Data in (A), (C) to (E), (G), and (H) are means ± SEM of three independent experiments. *P < 0.05; **P < 0.01; n.s., not significant.
with IgE and antigen (20) . Although the antigen-stimulated degranulation of CD40L-deficient BMMCs was comparable to that of wild-type BMMCs (Fig. 5E) , IgE-mediated anaphylaxis responses became more severe when the Kit W-sh/W-sh mice received CD40L −/− BMMCs instead of wild-type BMMCs (Fig. 5G) . Together, these results suggest that the CD40-CD40L interaction between CD5 + B cells and mast cells is critical for the suppression of mast cell activation and IgE-mediated PSA responses in vivo.
IL-10-producing CD5 + B cells inhibit FceRI-mediated signaling in mast cells
We did not observe any decrease in the cell surface abundances of the a, b, or g subunits of FceRI on BMMCs that were cocultured with CD5 + B cells for 24 hours (Fig. 6, A and B) . However, we observed alterations in the abundances of some tyrosine kinases that transduce initial signals after antigen-dependent cross-linking of IgE bound to FceRI. Coculture with wild-type CD5 + B cells, but not IL-10 −/− CD5 + B cells, substantially reduced the abundances of the kinases Fyn and Fgr in BMMCs, whereas Lyn and Syk were unaffected (Fig. 6, C and D) . The lack of change in the abundance of Syk was further confirmed by flow cytometric analysis (Fig. 6E) fig S5, A to D) . The essential requirement for an interaction between CD40 (on CD5 + B cells) and CD40L (on mast cells) to suppress the phosphorylation of the tyrosine kinases after IgE-and antigen-mediated stimulation was verified in experiments with an anti-CD40L antibody ( fig. S5, E and F) .
The inhibition of mast cells by IL-10 is dependent on signal transducer and activator of transcription 3 (STAT3) signaling, which leads to the reduced activation of tyrosine kinases involved in early signaling events (14) . We observed that IL-10 stimulated the phosphorylation of STAT3, which was inhibited by the Janus-activated kinase (JAK) inhibitor AG490 (Fig. 6H) . In addition, AG490 restored the abundance of Fyn and Fgr (Fig.  6I) as well as the extent of tyrosine phosphorylation of Syk in IL-10-treated BMMCs (Fig. 6J) . Further experiments showed that STAT3-specific small interfering RNA (siRNA) restored the amounts of Fyn and Fgr, as well as the phosphorylation of Syk, in IL-10-treated mast cells (Fig. 6, K and L) , which suggests that the suppression of mast cells by CD5 + B cell-derived IL-10 is mediated through the JAK-STAT3 pathway. 
DISCUSSION
B cells have the capacity to produce antibodies, function as APCs, and regulate the activation of CD4 + T cells (21) (22) (23) . In addition, there is evidence that B cells have a regulatory role in various immune responses through their production of cytokines. Katz et al. (24) were the first to demonstrate that the delayed-type hypersensitivity reaction was exacerbated by the depletion of B cells. Mizoguchi and Bhan (9) introduced the term "regulatory B cells" to designate negative regulatory subpopulations of B cells. B reg cells are now recognized as one of the key regulatory cell types that suppress inflammatory disorders (10) and various immune cells, including dendritic cells (DCs), macrophages, and T H cells (25, 26) .
IL-10 was originally identified as the T H 2 cell-derived cytokine synthesis inhibitory factor (27) , and it has broad anti-inflammatory actions. IL-10 suppresses the effector function of T cells and macrophages (28, 29) . With respect to B reg cells (B10 cells), IL-10 enables the suppressive functions of these cells in various immune disease models (10) . Moreover, subsets of IL-10-producing B reg cells suppress T H 2 cell-mediated allergic responses, including contact hypersensitivity and allergic airway disease in mouse models (7, 12) . Although mast cells can produce IL-10 through FceRIII signaling after the receptor is increased in abundance by IL-4 (30), IL-10 is not normally produced by mast cells through IgE-and antigenmediated stimulation ( fig. S3 , B and C).
Mast cells are the critical effector cells in food allergies, allergic asthma, and allergic rhinitis (16, 18) . Although present in multiple tissues, mast cells are distributed mainly at the major immunologic interfaces, such as the skin, gut, and lungs. Secondary lymphoid organs including spleens, tonsils, and lymph nodes harbor modest numbers of mast cells in physiological settings (19, 31) where they could also regulate inflammation. We previously reported that the prevalence of IL-10-producing CD5 + peripheral blood B cells increased in healthy donors but decreased in patients with milk allergy after challenge with milk antigen (32) . Our present finding that CD5 + B cells inhibited IgE-mediated mast cell activation and anaphylaxis in mice in an IL-10-dependent manner suggests that the interaction between IL-10-producing CD5 + B cells and mast cells provides a mechanism for counteracting allergic phenomena. IL-10, in particular, may provide another link between IL-10-producing CD5 + B cells and various immune cells, such as regulatory T cells, DCs, and eosinophils, in that it inhibits mast cell activation as well as allergic reactions (14, 33, 34) . As we reported here, production of IL-10 by CD5 + B cells is enhanced upon coculture with mast cells (Fig. 2, G to I) . The possible physical association between mast cells and CD5 + B cells was apparent from immunohistochemical analysis of the spleens of mice with PSA (Fig. 3D) and was verified by the observation that these cells form conjugates in coculture (Fig. 3,  B and C) . Therefore, the potential exists for crosstalk between these two cell types in physiological settings. Furthermore, direct cell-to-cell contact was essential for the production of IL-10 by CD5 + B cells, as well as for the inhibition of mast cell activation by CD5 + B cells. The interaction between CD40L and CD40 on T cells and B cells, respectively, is critical for CD4 + T cell activation and the effector functions of B cells (35) . Such an interaction may also stimulate the proliferation of IL-10-producing B reg cells in mice (36) and in patients with systemic lupus erythematosus (SLE) (37, 38) and thereby suppress the humoral response. Mast cells were reported to communicate with B cells and astrocytes through the CD40-CD40L interaction (39, 40) . Here, we propose that mast cells may similarly regulate CD5 + B cell function on the basis that mast cells express CD40L ( fig. S5D ) and increase the cell surface abundance of CD40 on CD5 + B cells, and that the CD40L-CD40 interaction leads to an increase in the number of IL-10-producing CD5 + B cells, which in turn suppress mast cell activation and anaphylaxis (Fig. 5) . Notably, the anaphylaxis responses stimulated by IgE and antigen were reduced in mice that received wild-type CD5 + B cells, but not CD40
−/− CD5 + B cells, by adoptive transfer (Fig. 5F ). To further determine whether CD40L on mast cells was critical for a direct interaction with CD40 on CD5 + B cells, we performed experiments with mast cell-deficient mice (Kit W-sh/W-sh mice), which do not show any PSA in response to IgE and antigen (20) . Although IgE-mediated anaphylaxis was not observed in Kit W-sh/W-sh mice (Fig. 5G) (20) , the responses became much more severe in mice that received CD40L −/− BMMCs by adoptive transfer compared to those that received wild-type BMMCs (Fig. 5G) . Together, these results suggest that CD40L on mast cells is critical to the induction of IL-10-producing CD5 + B cells in physiological settings. The precise details by which IL-10-producing B reg cells suppress allergic and inflammatory responses are unclear. Our results provide some insight with regard to the interaction of the B cells with mast cells. Early signaling events in antigen-stimulated mast cells include the recruitment of Lyn and other Src family kinases, such as Fyn (41) and Fgr (42) , to FceRI, which results in the phosphorylation and activation of Syk and the activation of mast cells (43) . In our experimental system, coculturing CD5 + B cells with BMMCs for 24 hours reduced the abundance of Fyn and Fgr in mast cells, and consequently decreased the phosphorylation of Syk (Fig.  6 , C to G), but had no effect on the abundances of individual FceRI subunits (Fig. 6B) . Similar results were obtained from experiments in which BMMCs were treated with recombinant IL-10 under similar conditions. However, more prolonged incubation (72 hours) of mast cells with IL-10 resulted in a reduction in the amounts of the FceRI subunits, in addition to a reduction in the abundances of Syk, Fyn, and Fgr in mast cells ( fig. S5, B and D) , consistent with previous findings (14) . We further demonstrated that the effects of CD5 + B cells on the abundances of Fyn and Fgr and on the phosphorylation of Syk were blocked by inhibiting the JAK-STAT3 pathway with a typical JAK inhibitor, AG490 (Fig. 6 , H to J), and by siRNAs specific for STAT3 in mast cells (Fig. 6 , K and L). These observations led us to suggest that CD5 + B cells inhibit mast cell activation through IL-10 by reducing the abundances of Fyn and Fgr through the JAK-STAT3 signaling pathway. It would be also of interest to determine (Fig. 7) . These findings suggest that IL-10-producing CD5 + B cells may provide an additional therapeutic target to treat IgE-mediated allergic diseases.
MATERIALS AND METHODS
Mice
Wild-type (~6-to 8-week-old male C57BL/6 mice), CD19
−/− [Cd19
), and Kit W-sh/W-sh mice were purchased from The Jackson Laboratory, housed in a specific pathogen-free animal facility at Konkuk University (Seoul, Korea) and fed with a sterilized diet and autoclaved water before being used for experiments. All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) at Konkuk University. 
Preparation and adoptive transfer of B cell subsets
Induction of PSA or PCA
Mice were primed with 3 mg of DNP-specific IgE (SPE-7; Sigma) by intravenous injection. On the next day, the mice were injected intravenously with 250 mg of DNP-BSA (Sigma) in 200 ml of PBS or as indicated in the figure legends. Rectal temperatures of the mice were measured every 10 min for 1 hour and 30 min after they were injected with antigen. For the histamine assay, the mice were euthanized with CO 2 30 min after they were injected with antigen, and serum was obtained by cardiac puncture. The concentration of histamine in the serum was measured by ELISA according to the manufacturer's instructions (Beckman Coulter). PCA was induced as described previously (43) . All experiments with mice were performed three times, with five mice for each condition used per experiment.
Flow cytometric analysis
Single-cell suspensions were isolated from the spleen, inguinal lymph node, peritoneal cavity, and blood. To detect intracellular IL-10 in B cells from each site, isolated B cells were cultured with medium alone or with medium containing BMMCs, IgE-treated BMMCs, IgE-and antigen-treated BMMCs, or CD40L (1 mg/ml; R&D Systems) for 24 hours or the times indicated in the figure legends, and phorbol 12-myristate 13-acetate (50 ng/ml; Sigma), ionomycin (500 ng/ml; Sigma), and brefeldin A (3 mg/ml; eBioscience) were added during the last 5 hours of incubation. Before cell surface markers were stained, Fcg receptors were blocked with anti-CD16 and anti-CD32 monoclonal antibodies (2.4G2, BD Biosciences), and conjugated and dead cells were excluded from the analysis on the basis of forward and side light scatter parameters and staining with Fixable Viability Dye (eBioscience). Cells were fixed and permeabilized with a Cytofix/Cytoperm kit (BD Biosciences) and then were incubated with anti-IL-10 monoclonal antibody (JES5-16E3, eBioscience) at 4°C for 30 min. The antibodies against cell surface proteins were as follows: anti-CD1d (1B1), anti-CD4 (RM4-5), anti-CD5 (53-7.3), anti-CD11b (M1/70), anti-CD19 (eBio1D3), anti-CD21/CD35 (eBioBD9), anti-CD23 (B3B4), anti-CD25 (PC61.5), anti-CD40 (HM40-3), anti-CD86 (GL1), anti-B220 (RA3-6B2), anti-IgD (11-26), anti-IgM (eB121-15 F9), anti-c-Kit (2B8), and anti-CD40L (MR1), which were purchased from eBioscience, and anti-FceRI (anti-IgE, R35-72), which was purchased from BD Biosciences. To detect FceRI subunits and intracellular Syk, fixed BMMCs were stained with antibodies against FceRIa (G-14), FceRIb (N-18), FceRIg (H-5), and Syk (N-19), which were obtained from Santa Cruz Biotechnology, and with anti-STAT3 antibody (M59-50), which was obtained from BD Biosciences. To evaluate the extent of phosphorylation of Syk or STAT3, BMMCs were primed with DNP-specific IgE (500 ng/ml) and cultured with CD5 + B cells for 24 hours before being stimulated with DNP-BSA (100 ng/ml) for 7 min (for pSyk) or 15 min (for pSTAT3). The BMMCs were immediately fixed and permeabilized and then were stained with anti-CD19 (eBio1D3), anti-c-Kit (2B8, eBioscience), and ei- BMMC differentiation and transfection with STAT3-specific siRNA BMMCs derived from C57BL/6 or BALB/c mice were cultured in RPMI 1640 medium containing 2 mM L-glutamine, 0.1 mM nonessential amino acids, antibiotics, 10% fetal bovine serum (FBS), and IL-3 (10 ng/ml; PeproTech Inc.). After 4 weeks, >98% of the cells were verified as BMMCs, as previously described (44) . BMMCs (5 × 10 6 cells) were transfected with 100 nM STAT3-specific siRNA or scrambled siRNA with an Amaxa Nucleofector (Lonza Cologne AG) with program T-5 in Dulbecco's modified Eagle's medium with 20% FBS and 50 mM Hepes (pH 7.5). Cells were used within 48 hours of transfection.
Measurement of degranulation and release of cytokines
BMMCs were primed for 4 hours with DNP-specific IgE (500 ng/ml; Sigma). The IgE-primed BMMCs were then stimulated with antigen [DNP-BSA (100 ng/ml); Sigma] in Tyrode-BSA buffer [20 mM Hepes (pH 7.4), 135 mM NaCl, 5 mM potassium chloride, 1.8 mM calcium chloride, 1 mM magnesium chloride, 5.6 mM glucose, and 0.05% BSA] for 15 min in the presence or absence of the B cell subsets indicated in the figure legends. Degranulation was determined by measuring the release of the granule marker b-hexosaminidase as previously described (45) . In some coculture experiments, BMMCs and B cell subsets were separated by 3.0-mm transwell membrane plates (Corning Life Sciences). Cells were stimulated with antigen for 24 hours (or the times indicated in the figure legends) in complete medium to measure the secretion of TNF-a, IL-4, and IL-10 with ELISA kits from Invitrogen (BioSource) or R&D Systems Inc.
Immunohistochemistry
Paraffin-embedded spleen sections were subjected to immunohistochemical analysis with specific antibodies and isotype controls according to a regular protocol. The signal was amplified with horseradish peroxidaseor alkaline phosphatase-conjugated streptavidin with a Vectastain Elite ABC kit (Vector). The sections were visualized with N-DAB or VectorRed, and then the mast cells were stained with toluidine blue.
Analysis of CD5
+ or CD5 − B cell-mast cell conjugation
IgE-primed or untreated BMMCs were stained with 1 mM CellTracker Green probe (BODIPY, Invitrogen), and isolated splenic CD5 + B cells were stained with 1 mM CellTracker Red probe (CMPTX, Invitrogen). The stained BMMCs (1 × 10 6 cells in 0.5 ml) were combined with 0.5 ml of stained CD5 + B cells (1 × 10 6 cells) at a cell/cell ratio of 1:1. The mixed cells were incubated with or without antigen (100 ng/ml) at 37°C for 45 min. Cells were then immediately fixed in 4% paraformaldehyde. Cell conjugates were determined by flow cytometric analysis with a FACSCalibur flow cytometer (Becton Dickinson).
Western blotting
After BMMCs were cocultured with wild-type or IL-10 −/− CD5 + B cells for 24 hours, CD19 microbeads (Miltenyi Biotec) were used to purify BMMCs by negative selection according to the manufacturer's instructions. The BMMCs were lysed in 100 ml of ice-cold lysis buffer containing a protease inhibitor cocktail tablet. The cell lysates were subjected to Western blotting analysis according to a standard protocol. Antibodies against FceRg and actin were purchased from Upstate Biotechnology; antibodies against FceRa, FceRb, Lyn, Fyn, Fgr, and Syk were obtained from Santa Cruz Biotechnology; and antibody against the phosphorylated form of Syk (pSyk) was purchased from Cell Signaling Technology.
Statistical analysis
Data were expressed as means ± SEM. Statistical analysis was performed by one-way analysis of variance and Dunnett's test. Statistical significance (*P < 0.05 and **P < 0.01) was determined with SigmaStat software (Systat Software Inc).
SUPPLEMENTARY MATERIALS
www.sciencesignaling.org/cgi/content/full/8/368/ra28/DC1 Fig. S1 . Analysis of the population of IL-10-producing CD5 + B cells involved in PSA. 
